Publications

Campbell MR, Ruiz-Saenz A, Zhang Y, Peterson E, Steri V, Oeffinger J, Sampang M, Jura N, Moasser MM. Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling. Cell reports. 2026. PMID: 42118658

Aggarwal R, Zhang J, Monk P, Zhu X, Jones R, Linch M, Costin D, de Bono J, Karsh LI, Petrylak DP, Zhang L, Deshpande R, Borderies P, Huang J, O'Neill V, Donkor M, Tagawa S. Phase 2 study of talabostat, a small molecule inhibitor of dipeptidyl peptidases (DPP), administered in combination with pembrolizumab in patients with small cell neuroendocrine prostate cancer. Journal for immunotherapy of cancer. 2026. PMID: 42114950

Nguyen LT, Hoyek C, Kapoor A, Magliano C, Mano MS, Prabhash K, Sonbol MB, Moraes FY, Van Loon K. Improving Affordability in Cancer Care for Resource-Limited Settings: Highlights From JCO Global Oncology. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2026. PMID: 42114030

Huang F, Song H, Xu J, Velazquez-Arcelay K, Demirci A, Raizenne B, Hsu S, Choi J, Pham J, Chen YA, Weinstein H, Salzman I, Tsui M, Akutagawa J, Adingo W, Goldschmidt E, Carroll P, Hong J, Heaphy C, Cooperberg M, Greenland N, Campbell J. Defining the combinatorial nature of gene modules in prostate cancer underlying lineage plasticity and metastasis. Research square. 2026. PMID: 42183352

Truong AA, Ho S, Lee RH, Wu X, Kang H, El-Sayed IH, George JR, Heaton CM, Likhterov I, Xu MJ, Ha PK, Algazi AP, Wai KC. Neutrophil-To-Lymphocyte Ratio and Survival in Pembrolizumab-Treated Oropharyngeal Cancer. Head & neck. 2026. PMID: 42108213

Rimassa L, Chan SL, Sangro B, Lau G, Kudo M, Reig M, Breder V, Ryu MH, Ostapenko Y, Sukeepaisarnjaroen W, Varela M, Tougeron D, Crysler OV, Bouattour M, Dao TV, Tam VC, Faccio A, Furuse J, Jeng LB, Kang YK, Kelley RK, Kurland JF, Balaji K, Abou-Alfa GK. Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver cancer). Future oncology (London, England). 2026. PMID: 42108643

Zeng J, Cheng Z, Chen H, Thompson J, Crosby KT, Han H, Ngo W, Xia C, Rosas-Rivera D, Kang MH, Mao Y, Lee G, Diffley JFX, Song Y, Qiu L, Krah NM, Murthy N, Jackson RN, Liu Y, Ashworth A, Doudna JA. Selective Elimination of TP53 Mutant Cells by Transcript-Activated Chromatin Shredding. bioRxiv : the preprint server for biology. 2026. PMID: 42146678

Marrero Morales LS, Al-Qaraghli MI, Polen K, Selekwa M, Yeh T, Charles-Obi K, Sang'udi S, Muhunzi D, Liang E, Kivuyo NE, Mushi BP, Maina IW, Mmbaga EJ, Van Loon K, Xu MJ, Gaskill CE, Ibrahim PM. The current landscape and opportunities in gastrostomy care quality improvement in low- and middle-income countries: a scoping review. International health. 2026. PMID: 42104811

Brufsky A, Layman RM, Liu X, Li B, McRoy L, Cohen A, Estevez M, Cottu P, Thill M, Curigliano G, Rugo HS. Real-world treatment durations, subsequent treatments, and switching of CDK4/6 inhibitors among patients with HR+/HER2- metastatic breast cancer. The oncologist. 2026. PMID: 42095602

Lord CJ, Tutt ANJ, Ashworth A. Two decades of PARP inhibitor synthetic lethality in cancer. Nature. 2026. PMID: 42092061

Rajeeve S, Wilkes M, Zahradka N, Tomalin L, Quidwai M, Pan D, Calafat NJ, Cusack M, Aleman A, Serebryakova K, Kappes K, Jackson H, Agte S, Thibaud S, Sanchez L, Richard S, Richter J, Rodriguez C, Cho HJ, Chari A, Jagannath S, Laganà A, Rossi AC, Parekh S. Detection of cytokine release syndrome using wearables and cytokine profiling following CAR-T therapy for myeloma. JCI insight. 2026. PMID: 42084945

Bahlis NJ, Facon T, San-Miguel JF, Usmani SZ, Dimopoulos MA, Moreau P, Zweegman S, Perrot A, Manier S, Chari A, Raje NS, Orlowski RZ, Goldschmidt H, Basu S, Hulin C, Weisel KC, Mohty M, Leleu X, Plesner T, Jakubowiak AJ, Cook G, Quach H, Venner CP, Cavo M, Ngo M, Bolyard K, Carson R, Borgsten F, Mateos MV, Kumar SK. Infections in Patients Receiving Daratumumab for Newly Diagnosed Multiple Myeloma: A Pooled Analysis of MAIA and ALCYONE. Blood advances. 2026. PMID: 42085642

Lacouture ME, Pan A, Maier T, Chen A, Dranitsaris G, Shah NJ, Dang C, Gajria D, Gordon A, Iyengar N, Razavi P, Robson M, Rosen E, Wong S, Harris U, Ketosugbo K, Bravo C, Jain M, Markova A. Benralizumab relieves Eosinophil-Related Cutaneous Adverse Events from Cancer Therapy: A Nonrandomized Phase 2 Trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2026. PMID: 42084605

Orgeta V, Kidd G, Stafford J, Leung P, Marston L, Sidebottom A, Fong L. Characteristics of missing incidents and risk factors for harm for older people with and without dementia in the UK. Age and ageing. 2026. PMID: 42120014

Odintsov I, Tazelaar HD, Lee JC, Damon LE, Devine WP, Jones KD. Novel BRAF fusion in Erdheim-Chester disease with pulmonary manifestations: Importance of RNA-based testing and response to MEK inhibition. Histopathology. 2026. PMID: 42082348

Stauffer C, Brantly NW, Beam DW, Bose R, Fiedler G, Fisher LE. 3D printing and prostheses: The current state-of-the-art and future directions. Journal of rehabilitation and assistive technologies engineering. 2026. PMID: 42124558

Chow R, Zhang D, Kannout S, Ma A, Zheng C, Blayne A, Dou A, Talwar S, Fazelzad R, Rugo HS, Ruhlmann CH, Iihara H, Affronti ML, Leigh J, Scotté F, Eng L, MASCC Antiemetic Study Group and the MASCC Emerging Toxicities Study Group. Prevalence of antibody drug conjugated-induced nausea and vomiting (ADCINV) in patients with cancer. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2026. PMID: 42068413

Khozin S, Dreyer NA, Galante D, Liu R, Neumann P, Nussbaum N, O'Shaughnessy J, Rimawi MF, Rugo HS, Tolaney SM, Weiss M, Brufsky A. Clinically Meaningful, Patient-Centered Endpoints for Real-World Evidence Generation in Breast Cancer: Perspectives from the Multidisciplinary TRIUMPH Initiative. Advances in therapy. 2026. PMID: 41843049

Venook AP. How to implement DPYD genotyping into practice. Clinical advances in hematology & oncology : H&O. 2026. PMID: 42096684

Widder J, Bol GM, Simek IM, Ehret F, Abdel-Aty H, Basic S, Chuter D, Daly J, Fairbrother P, Zeqa D, Aboubakar Nana F, Achard V, Corradini S, Correia D, De Ruysscher D, Dingemans AC, Faivre-Finn C, Gillessen S, Guren MG, Hendriks L, Kunz WG, Lecouvet FE, Levy A, Lievens Y, McDonald F, Meattini I, Oppong F, Oprea-Lager D, Palma D, Fredberg Persson G, Remon J, Vandemaele M, van Laarhoven HWM, Verkooijen HM, Visani L, Zilli T, Ost P, Guckenberger M. Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC-ESTRO OligoCare consortium. The Lancet. Oncology. 2026. PMID: 42061381